

# Kosuke Hamai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6537057/publications.pdf>

Version: 2024-02-01

6  
papers

161  
citations

1937685

4  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

296  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small cell lung cancer expressing high PD-L1. <i>Thoracic Cancer</i> , 2022, 13, 1611-1618.	1.9	4
2	Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. <i>European Journal of Cancer</i> , 2021, 149, 14-22.	2.8	30
3	First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1 : A case report. <i>Thoracic Cancer</i> , 2020, 11, 1716-1719.	1.9	2
4	Use of proton pump inhibitors is associated with increased mortality due to nosocomial pneumonia in bedridden patients receiving tube feeding. <i>Geriatrics and Gerontology International</i> , 2018, 18, 1215-1218.	1.5	8
5	Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. <i>BMC Medical Genetics</i> , 2017, 18, 88.	2.1	26
6	Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis. <i>Disease Markers</i> , 2016, 2016, 1-8.	1.3	91